Literature DB >> 10664282

Medical treatment of primary sclerosing cholangitis.

Y M Lee1, M M Kaplan.   

Abstract

Until 1970, primary sclerosing cholangitis (PSC) was considered to be a medical curiosity. With the development of endoscopic cholangiography, PSC is now recognized more frequently and is a common indication for liver transplantation. PSC is usually progressive, leading to cirrhosis, portal hypertension, and liver failure. The manifestations of disease may be clinically similar to those of other causes of bile duct obstruction and must be distinguished from gallstone disease, bile duct carcinoma, primary biliary cirrhosis, and secondary biliary cirrhosis due to bile duct stricture. Medical management of PSC must take into account the likelihood that destroyed bile ducts do not regenerate as hepatocytes do. Hence, PSC should be treated early in its course. The goal of therapy is to prevent further damage and destruction of bile ducts. In this article, we will present relevant data concerning the medical management of primary sclerosing cholangitis.

Entities:  

Mesh:

Year:  1999        PMID: 10664282     DOI: 10.1007/s005340050131

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  2 in total

1.  Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.

Authors:  Ryuichi Kita; Seigo Takamatsu; Toru Kimura; Hiroyuki Kokuryu; Yukio Osaki; Naomi Tomono
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

Review 2.  The medical management of primary sclerosing cholangitis.

Authors:  Anthony Michaels; Cynthia Levy
Journal:  Medscape J Med       Date:  2008-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.